Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors

US6962915B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Jagabandhu Das · Mercerville, US
• Chunjian Liu · Pennington, US
• Robert V. Moquin · East Brunswick Township, US
• Katerina Leftheris · Skillman, US

Key dates

• Filing date: May 19, 2003
• Grant date: Nov 8, 2005
• Expiry date: May 19, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the formula (I), and pharmaceutically acceptable salts or prodrugs thereof, are useful as kinase inhibitors, wherein Y is —C(═O)NR1—, —NR1C(═O)—, —NR1C(═O)NR1—, —NR1SO2—, —SO2NR1—, —C(═O)—, —OC(═O)—, or —CO2—; B is alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxy, alkoxy, aryl, cycloalkyl, heteroaryl, and heterocyclo; or when Y is —C(═O)NR1—, B also may be selected from —C(═O)R8, —C(═O)NR8R9, and —CO2R8; R1 is hydrogen, C1-4alkyl, or substituted C1-4alkyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen, methyl, perfluoromethyl, hydroxy, methoxy, halogen, cyano, NH2, or NH(CH3); and R4, R5, R6, R7, R8, and R9 are as defined in the specification.